Figure 2.
Inhibition of IL-2 production in IL-15-deficient mice. (A) IL-2 production by IL-15-deficient, IL-2Rγ-deficient, and WT BMDCs after zymosan A, CpG, and LPS stimulation. (B) Activation profile of BMDCs after stimulation with zymosan. B7-2 molecule expression of unstimulated DCs (solid lines) and after 24-hour zymosan activation (dotted lines). (C) In vivo IL-2 production by DCs after LPS treatment. LPS was injected into WT or IL-15-deficient mice. Three hours later, CD11c+ cells were purified from the spleen and double stained with anti-CD11c and anti-IL-2 or isotype control antibodies. Some sorted cells were put in culture; after 24 hours, the production of IL-2 and IL-12p70 in the supernatant was measured. Panels A, B, and C are representative of 1 experiment each of 3 independent experiments with comparable results.

Inhibition of IL-2 production in IL-15-deficient mice. (A) IL-2 production by IL-15-deficient, IL-2Rγ-deficient, and WT BMDCs after zymosan A, CpG, and LPS stimulation. (B) Activation profile of BMDCs after stimulation with zymosan. B7-2 molecule expression of unstimulated DCs (solid lines) and after 24-hour zymosan activation (dotted lines). (C) In vivo IL-2 production by DCs after LPS treatment. LPS was injected into WT or IL-15-deficient mice. Three hours later, CD11c+ cells were purified from the spleen and double stained with anti-CD11c and anti-IL-2 or isotype control antibodies. Some sorted cells were put in culture; after 24 hours, the production of IL-2 and IL-12p70 in the supernatant was measured. Panels A, B, and C are representative of 1 experiment each of 3 independent experiments with comparable results.

Close Modal

or Create an Account

Close Modal
Close Modal